. Author manuscript; available in PMC: 2009 Sep 15.

Published in final edited form as: Adv Drug Deliv Rev. 2008 Apr 24;60(12):1407–1420. doi: 10.1016/j.addr.2008.04.011

Table 2.

Antibodies and immunoconjugates approved in the US for human use in treating cancer.

Generic name	Tradename (specificity)	Approved Use
Unconjugated antibodies
Alemtuzumab	Campath (humanized anti-CD52)	second-line treatment of chronic B-lymphocytic leukemia who failed fludarabine.
Bevacizumab	Avastin (humanized anti-VEGF)	combined with intravenous 5-FU-based chemotherapy for first or second line therapy of colorectal cancers.
		combined with carboplatin and paclitaxel for first line unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer
Cetuximab	Erbitux (chimeric anti-EGFR IgG)	combined with irinotecan for metastatic colon cancer or alone in patients unable to tolerate irinotecan.
		combined with radiation therapy in head and neck cancer (locally or regionally advanced) or as a single agent in patients with recurrent, or metastatic squamous carcinoma of head and neck who failed platinum-based therapy.
Panitumumab	Vectibix (human anti-EGFR IgG)	second-line in patients who failed FOLFOX or FOLFIRI chemotherapy regimens
Rituximab	Rituxan (chimeric anti-CD20 IgG)	relapsed low-grade or follicular non-Hodgkin’s lymphoma (NHL)
		first-line treatment follicular NHL in combination with CVP chemotherapy
		first-line treatment of diffuse large B-cell NHL in combination with CHOP or other anthracyclinesbased chemotherapy;
		low-grade NHL with stable disease or who achieve a partial or complete response following CVP chemotherapy
Trastuzumab	Herceptin (humanized anti-HER2 IgG)	single agent in patients with metastatic breast cancer that overexpress HER2 and who have received one or more chemotherapy regimens;
		combined with doxorubicin, cyclophosphamide, and paclitaxel in an adjuvant setting for nodepositive breast cancer;
		combined with paclitaxel in patients with metastatic breast who have not received treatment for their metastatic disease.
Radiolabeled antibodies
Ibritumomab tiuxetan	Zevalin (murine anti-CD20 IgG-DTPA conjugate; radiolabeled with ⁹⁰Y or ¹¹¹In; rituximab pre-dose)	treatment of relapsed or refractory low-grade, follicular or transformed B-cell NHL.
Tositumomab	Bexxar (murine anti-CD20 IgG; radiolabeled with ¹³¹I; tositumomab pre-dose)	treatment of patients with refractory, low-grade, follicular, or transformed NHL, including patients with rituximab-refractory NHL
Antibody-drug conjugate
gemtuzumab ozogamicin	Mylotarg (humanized anti-CD33 IgGcolecheamicin	acute myeloid leukemia in first relapse and patients ≥60 yr old who are not candidates for other cytotoxic therapy.